(Q38172608)

30 August 2017

title

Emerging protein kinase inhibitors for non-small cell lung cancer (English)

1 reference

30 August 2017

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Stephen V Liu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

Subramaniam Nachimuthu Deepa

11 June 2020

2

object named as

Deepa Subramaniam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

George C Cyriac

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Feras J Abdul-Khalek

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

20 December 2013

1 reference

Expert Opinion on Emerging Drugs

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

51-65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Signal transduction by allosteric receptor oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Growth factor signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Identification of ROS1 rearrangement in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

BRAF in melanoma: current strategies and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

A patient with lung adenocarcinoma and RET fusion treated with vandetanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Tobacco cessation and control a decade later: American society of clinical oncology policy statement update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2014.873403

10.1517/14728214.2014.873403

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24354593%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference